Management of Antiplatelet and Anticoagulant Therapy After Intracranial Hemorrhage

Immediate Management and Risk Assessment

The European Society of Cardiology recommends that all antiplatelet and anticoagulant therapy should be immediately stopped upon recognition of intracranial hemorrhage, and resumption of anticoagulation should generally occur after 4-8 weeks 1, 2, 3
The American Heart Association suggests that emergency brain imaging with neurological and neurosurgical consultation is required upon recognition of intracranial hemorrhage 4
Consideration of reversal agents such as protamine for heparin, fresh frozen plasma, prothrombin complex concentrates, activated factor VII, and platelets is necessary as clinically indicated 4
Identification and treatment of modifiable bleeding risk factors, particularly uncontrolled hypertension, is crucial 1, 2
Documentation of hemorrhage location (lobar vs. deep) is significant as it impacts recurrence risk and resumption decisions 2, 3

The European Heart Journal recommends that for patients requiring anticoagulation, resumption may occur after 4-8 weeks provided the cause of bleeding or relevant risk factors have been treated or controlled 1
A survival model suggests the optimal timing is approximately 10 weeks, minimizing the combined risk of ischemic plus hemorrhagic stroke 2, 3
Delay of at least 1 month is recommended based on observational data showing early resumption increases rebleeding risk more than thromboembolism risk from withholding 2, 3

For lobar intracranial hemorrhage, anticoagulation should generally be avoided long-term due to a 15% annual recurrence risk 2, 3
For deep intracranial hemorrhage, anticoagulation can be considered if thromboembolism risk is particularly high, as recurrence risk is substantially lower 2, 3

For mechanical prosthetic heart valves, especially cage-ball valves in mitral position, early resumption may be necessary due to extremely high embolism risk 2, 5, 3

The European Heart Journal recommends preferring NOACs (direct oral anticoagulants) over warfarin when resuming, as they convey lower intracranial hemorrhage risk 1
Consideration of anticoagulants with the lowest bleeding risk profile available is necessary 1

Antiplatelet agents do not appear to dramatically increase hematoma expansion risk and are generally safer than anticoagulants after intracranial hemorrhage 2, 3
Observational data shows antiplatelet resumption is associated with lower ischemic events without increased hemorrhagic events 6
Small studies suggest early resumption within 30 days of intracranial hemorrhage appears safe, though selection bias may affect these findings 6

The European Heart Journal suggests aspirin should be considered for secondary stroke prevention until oral anticoagulation can be safely reinitiated in atrial fibrillation patients 1
This provides some protection against thromboembolism during the anticoagulation-free period 1

Never resume anticoagulation before 4 weeks unless extremely high thromboembolism risk (prosthetic valves) 2, 3
Do not initiate antiplatelet therapy before 24-hour post-thrombolysis imaging confirms absence of hemorrhage 7
Avoid warfarin if possible; NOACs have a superior safety profile for intracranial hemorrhage risk 1
Do not combine anticoagulation with antiplatelet therapy routinely after intracranial hemorrhage 1
Avoid triple therapy (anticoagulation + dual antiplatelet) except for the shortest possible duration after PCI 8